HTRF CD16a and variants binding assays for the cell-based characterization of therapeutic antibodies and for ADCC prediction
The CD16a cellular binding assays are simple and robust tests to monitor binding of the IgG Fc region to the human CD16a receptor (or FcγIIIRa) on live cells and to select the most potent antibody for use in Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). The assays can also be used to assess the degree of antibody afucosylation. Two separate CD16a assays are available to specifically target the V158 or F158 variants. These assays, based on our innovative tag-lite technology, can easily be automated to create a high-throughput solution for predicting ADCC.
The contribution of IgG Fc-mediated effector functions in ADCC has motivated the efforts being made to enhance interactions with Fc gamma receptors (FcγRs) for the development and manufacturing of therapeutic antibodies. In humans, Fc gamma Rs are divided into three groups, known as CD64 (FcγRI), CD32 (FcγRI) and CD16 (FcγRIII). Cisbio Bioassays has developed a cell-based FcR assay platform for selective antibody binding analyses using each type of receptor.
NEW! The FcR platform has been extended to neonatal Fc-receptor in a biochemical assay.